HealthyEarly Phase 1NCT06800183
Topical Tartrazine for Improved Skin Structure Visualization in Dermatology
A Early Phase 1 study testing Four-Chamber Tartrazine Patch across 3 Body Sites in people with Healthy and Dermoscopy, run by Johns Hopkins University at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if the topical application of tartrazine, an FDA-approved food dye, can help improve the transparency of the skin in healthy volunteers. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy, Dermoscopy, Optical Imaging
- What is being tested?
- Four-Chamber Tartrazine Patch across 3 Body Sites
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 11 May 2026to Dec 2026
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy adults aged 18 and older
- Willingness to comply with study procedures
- Able to provide informed consent
Who cannot join
- Known allergies to tartrazine or related compounds
- Current or history of skin conditions such as eczema, psoriasis, or severe inflammatory diseases, defined as scoring ≥16 on the Eczema Area and Severity Index (EASI) or ≥10 on the Psoriasis Area Severity Index (PASI)
- Other atopic conditions such as asthma, allergic rhinitis, or hypersensitivity reactions
- Pregnancy or breastfeeding
- Use of immunosuppressive medications
- Any condition that may interfere with the safety or results of the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Topical Application of Tartrazine for Enhanced Visualization of Subcutaneous Structures in Dermatology
The goal of this clinical trial is to learn if the topical application of tartrazine, an FDA-approved food dye, can help improve the transparency of the skin in healthy volunteers. The main questions it aims to answer are:
- Can topical tartrazine application allow for temporary skin transparency?
- What dose of tartrazine is required to achieve reversible skin transparency?
Participants will:
- Be given a patch test with four different doses of tartrazine
- Have these patch tests placed on the back, stomach, and forearm
- Have photographs taken every 5 minutes to see if transparency is achieved
- Be called 48 hours later to check for any side effects
Read the detailed description
Optical imaging of biological tissues is limited by unwanted scattering and absorption of light, which restricts both the depth of imaging and the spatial resolution. This scattering occurs due to refractive index (RI) mismatches between different tissue components, such as the low RI of water-rich cytosol and the high RI of lipid-based structures. Current methods to reduce light scattering, such as the use of optical clearing agents (OCAs), often involve toxic chemicals or removal of tissue components, making them unsuitable for live imaging.
A recently published study in Science demonstrated that tartrazine, a commonly utilized food dye, is a potent OCA that achieves temporary optical transparency in living tissues. In rodent models, tartrazine was topically administered in a 0.6 M solution and showed reversible transparency effects and rendered their skin, muscle and connective tissues transparent while also providing high-resolution imaging down to the micrometer level without causing tissue damage. Imaging techniques such as laser speckle contrast imaging revealed clear visualization of cerebral blood vessels and internal organs, without needing to surgically remove tissue. Topical application in rodents caused minimal inflammation as affirmed by histological analysis. Additionally, the dye was rapidly cleared via urine and feces without signs of systemic toxicity, and after application, the dye can be washed out to further reduce exposure.
Compared to additional OCAs, tartrazine diffused through tissues more rapidly and required lower concentrations to achieve the desired transparency, resulting in faster visualization. Unlike conventional agents, tartrazine did not cause side effects such as tissue shrinkage or dehydration, making it a promising alternative for non-invasive imaging. These studies established that tartrazine, a strongly absorbing molecule, can reduce the RI mismatch between water and lipids, effectively minimizing light scattering and improving optical transparency.
Tartrazine, also known as FD\&C Yellow No. 5, is a commonly utilized coloring agent found in food products, cosmetics, and medications with approved safety profiles across multiple regulatory bodies, including the US Food and Drug Administration (FDA), Joint Food and Agriculture Organization (FAO) and World Health Organization (WHO) Expert Committee on Food Additives (JECFA), and European Food Safety Authority (EFSA). Although tartrazine has been widely used in food and cosmetics, its clinical use for enhancing reversible skin transparency remains under-explored. The long-standing safety profile of tartrazine, in conjunction with the promising preclinical imaging modulation effects, justifies investigating its efficacy in humans.
Existing optical imaging techniques are limited by penetration depth and high scattering, particularly in vivo. This study aims to fill this gap by using tartrazine to improve visualization in human subjects. The potential benefits of this non-invasive technique for human applications are vast, particularly in dermatology, tumor imaging, and surgical planning. If successful, tartrazine could enable clearer, non-invasive imaging of tumors, vascular lesions, and other subcutaneous structures - providing real-time insights into disease progression and aiding in more accurate medical interventions. This clinical pilot study, with a primary focus on the feasibility of topical tartrazine for improving skin transparency, is built upon the promising results from rodent models and tartrazine's well-established safety profile in humans.
- Conditions
- Healthy, Dermoscopy, Optical Imaging
- Being tested
- Four-Chamber Tartrazine Patch across 3 Body Sites
- Keywords
- Tartrazine, optical transparency, dermoscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Four-Chamber Tartrazine Patch across 3 Body SitesDrug
Also called FD&C Yellow 5, E102
This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses.
| Study group | Role | What they receive |
|---|---|---|
| Tartrazine Patch with 4 Doses across 3 Body Sites | Experimental | A four-chamber patch will be loaded with 0.5militer (mL) of tartrazine and applied to 1 cm diameter areas on the skin. Each chamber will deliver one of four different concentrations of a tartrazine solution-0.15 molar concentration (M), 0.3M, 0.6M, and 1.2M-on three distinct skin regions: the anterior forearm (representing thin skin), the abdomen (representing medium-thickness skin), and the back (representing thicker skin). This method ensures consistent, standardized, and simultaneous applications across all skin types and participants, reducing variability in the application process. Receives: Drug: Four-Chamber Tartrazine Patch across 3 Body Sites |
What is being measured
The primary outcome is the main question the study is designed to answer.
Optical Transparency as Assessed by Total Transmittance Percentage
To determine the optimal duration for maximum transparency, serial imaging will be conducted over the course of one 90 minute clinic visit (baseline, immediately post-application, and at 5-minute intervals until transparency plateaus). Imaging will be performed using non-invasive modalities. High-resolution dermoscopy will capture clear images of skin structures, and standardized high-quality photography will document the visible effects of transparency. These images will assess improvements in the resolution, depth, and overall image quality of subdermal structures, allowing the investigators to evaluate whether tartrazine significantly enhances visualization.
Measured: Up to 90 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2025
- Study start11 May 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Why it stopped: The investigators are revisiting in vitro and in vivo studies to ensure the ability to replicate the results of the original paper before proceeding to the pilot clinical study.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Johns Hopkins UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Joel Sunshine, MD, PhD, Principal investigator, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06800183
- Sponsor's protocol ID
- IRB00469443
- Status last verified
- Nov 2025
- First submitted
- 23 Jan 2025
- Last updated
- 14 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ntziachristos V. Going deeper than microscopy: the optical imaging frontier in biology. Nat Methods. 2010 Aug;7(8):603-14. doi: 10.1038/nmeth.1483. Epub 2010 Jul 30.
PubMed 20676081Ou Z, Duh YS, Rommelfanger NJ, Keck CHC, Jiang S, Brinson K Jr, Zhao S, Schmidt EL, Wu X, Yang F, Cai B, Cui H, Qi W, Wu S, Tantry A, Roth R, Ding J, Chen X, Kaltschmidt JA, Brongersma ML, Hong G. Achieving optical transparency in live animals with absorbing molecules. Science. 2024 Sep 6;385(6713):eadm6869. doi: 10.1126/science.adm6869. Epub 2024 Sep 6.
PubMed 39236186
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Topical Application of Tartrazine for Enhanced Visualization of Subcutaneous Structures in Dermatology
- ClinicalTrials.gov ID
- NCT06800183
- Acronym / sponsor ID
- IRB00469443
- Conditions
- Healthy, Dermoscopy, Optical Imaging
- Keywords
- Tartrazine, optical transparency, dermoscopy
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: The investigators are revisiting in vitro and in vivo studies to ensure the ability to replicate the results of the original paper before proceeding to the pilot clinical study.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Johns Hopkins UniversityUniversity, hospital or other
- Study start
- 11 May 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 29 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if the topical application of tartrazine, an FDA-approved food dye, can help improve the transparency of the skin in healthy volunteers. The main questions it aims to answer are:
- Can topical tartrazine application allow for temporary skin transparency?
- What dose of tartrazine is required to achieve reversible skin transparency?
Participants will:
- Be given a patch test with four different doses of tartrazine
- Have these patch tests placed on the back, stomach, and forearm
- Have photographs taken every 5 minutes to see if transparency is achieved
- Be called 48 hours later to check for any side effects
Detailed description
Optical imaging of biological tissues is limited by unwanted scattering and absorption of light, which restricts both the depth of imaging and the spatial resolution. This scattering occurs due to refractive index (RI) mismatches between different tissue components, such as the low RI of water-rich cytosol and the high RI of lipid-based structures. Current methods to reduce light scattering, such as the use of optical clearing agents (OCAs), often involve toxic chemicals or removal of tissue components, making them unsuitable for live imaging.
A recently published study in Science demonstrated that tartrazine, a commonly utilized food dye, is a potent OCA that achieves temporary optical transparency in living tissues. In rodent models, tartrazine was topically administered in a 0.6 M solution and showed reversible transparency effects and rendered their skin, muscle and connective tissues transparent while also providing high-resolution imaging down to the micrometer level without causing tissue damage. Imaging techniques such as laser speckle contrast imaging revealed clear visualization of cerebral blood vessels and internal organs, without needing to surgically remove tissue. Topical application in rodents caused minimal inflammation as affirmed by histological analysis. Additionally, the dye was rapidly cleared via urine and feces without signs of systemic toxicity, and after application, the dye can be washed out to further reduce exposure.
Compared to additional OCAs, tartrazine diffused through tissues more rapidly and required lower concentrations to achieve the desired transparency, resulting in faster visualization. Unlike conventional agents, tartrazine did not cause side effects such as tissue shrinkage or dehydration, making it a promising alternative for non-invasive imaging. These studies established that tartrazine, a strongly absorbing molecule, can reduce the RI mismatch between water and lipids, effectively minimizing light scattering and improving optical transparency.
Tartrazine, also known as FD\&C Yellow No. 5, is a commonly utilized coloring agent found in food products, cosmetics, and medications with approved safety profiles across multiple regulatory bodies, including the US Food and Drug Administration (FDA), Joint Food and Agriculture Organization (FAO) and World Health Organization (WHO) Expert Committee on Food Additives (JECFA), and European Food Safety Authority (EFSA). Although tartrazine has been widely used in food and cosmetics, its clinical use for enhancing reversible skin transparency remains under-explored. The long-standing safety profile of tartrazine, in conjunction with the promising preclinical imaging modulation effects, justifies investigating its efficacy in humans.
Existing optical imaging techniques are limited by penetration depth and high scattering, particularly in vivo. This study aims to fill this gap by using tartrazine to improve visualization in human subjects. The potential benefits of this non-invasive technique for human applications are vast, particularly in dermatology, tumor imaging, and surgical planning. If successful, tartrazine could enable clearer, non-invasive imaging of tumors, vascular lesions, and other subcutaneous structures - providing real-time insights into disease progression and aiding in more accurate medical interventions. This clinical pilot study, with a primary focus on the feasibility of topical tartrazine for improving skin transparency, is built upon the promising results from rodent models and tartrazine's well-established safety profile in humans.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Tartrazine Patch with 4 Doses across 3 Body Sites | Experimental | Drug: Four-Chamber Tartrazine Patch across 3 Body SitesA four-chamber patch will be loaded with 0.5militer (mL) of tartrazine and applied to 1 cm diameter areas on the skin. Each chamber will deliver one of four different concentrations of a tartrazine solution-0.15 molar concentration (M), 0.3M, 0.6M, and 1.2M-on three distinct skin regions: the anterior forearm (representing thin skin), the abdomen (representing medium-thickness skin), and the back (representing thicker skin). This method ensures consistent, standardized, and simultaneous applications across all skin types and participants, reducing variability in the application process. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Healthy adults aged 18 and older
- Willingness to comply with study procedures
- Able to provide informed consent
Key exclusion criteria (6 listed)
- Known allergies to tartrazine or related compounds
- Current or history of skin conditions such as eczema, psoriasis, or severe inflammatory diseases, defined as scoring ≥16 on the Eczema Area and Severity Index (EASI) or ≥10 on the Psoriasis Area Severity Index (PASI)
- Other atopic conditions such as asthma, allergic rhinitis, or hypersensitivity reactions
- Pregnancy or breastfeeding
- Use of immunosuppressive medications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Four-Chamber Tartrazine Patch across 3 Body SitesAlso: FD&C Yellow 5, E102This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses. | Drug | Tartrazine Patch with 4 Doses across 3 Body Sites |
Primary outcome
Optical Transparency as Assessed by Total Transmittance Percentage
Time frame: Up to 90 minutes
To determine the optimal duration for maximum transparency, serial imaging will be conducted over the course of one 90 minute clinic visit (baseline, immediately post-application, and at 5-minute intervals until transparency plateaus). Imaging will be performed using non-invasive modalities. High-resolution dermoscopy will capture clear images of skin structures, and standardized high-quality photography will document the visible effects of transparency. These images will assess improvements in the resolution, depth, and overall image quality of subdermal structures, allowing the investigators to evaluate whether tartrazine significantly enhances visualization.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2025.
- Results publication: PubMed 20676081Ntziachristos V. Going deeper than microscopy: the optical imaging frontier in biology. Nat Methods. 2010 Aug;7(8):603-14. doi: 10.1038/nmeth.1483. Epub 2010 Jul 30.
- Results publication: PubMed 39236186Ou Z, Duh YS, Rommelfanger NJ, Keck CHC, Jiang S, Brinson K Jr, Zhao S, Schmidt EL, Wu X, Yang F, Cai B, Cui H, Qi W, Wu S, Tantry A, Roth R, Ding J, Chen X, Kaltschmidt JA, Brongersma ML, Hong G. Achieving optical transparency in live animals with absorbing molecules. Science. 2024 Sep 6;385(6713):eadm6869. doi: 10.1126/science.adm6869. Epub 2024 Sep 6.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joel Sunshine, MD, PhD principal investigator
Johns Hopkins University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Four-Chamber Tartrazine Patch across 3 Body Sites in people with Healthy and Dermoscopy, run by Johns Hopkins University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 14 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Optical Transparency as Assessed by Total Transmittance Percentage (time frame: Up to 90 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06800183, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2025.